3 articles
BioNTech will close manufacturing sites in Germany and Singapore after failing to find buyers, resulting in up to 1,860 job cuts. This restructuring follows the transfer of COVID-19 vaccine production
BioNTech reduced its 2026 revenue guidance to €1.6-1.9 billion due to softening COVID vaccine demand, with Q2 revenue falling over 50%. The German pharma company also appointed a new CEO and plans to
Moderna CEO Stephane Bancel expressed interest in acquiring BioNTech's planned-to-close German production facilities, citing them as a cost-effective alternative to new builds pending government partn
ChemBrief